ClinicalTrials.Veeva

Menu

BCMA-CS1 Compound CAR (cCAR) T Cells for Relapsed/Refractory Multiple Myeloma

I

iCell Gene Therapeutics

Status and phase

Unknown
Early Phase 1

Conditions

Multiple Myeloma

Treatments

Biological: BCMA-CS1 cCAR T cells

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT04156269
ICG182-001

Details and patient eligibility

About

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CS1 cCAR in patients with relapsed and/or refractory multiple myeloma.

Full description

BCMA-CS1 cCAR (Compound CAR BCMA-CS1) is a chimeric antigen receptor immunotherapy treatment designed to treat multiple myeloma using two different antigen targets, BCMA (CD269) and CS1 (SLAMF7).

The use of two different targets widely expressed on plasma cells, BCMA and CS1, intends to increase coverage and eradicate cancerous cells before resistance develops in surviving cancer cells that have undergone selective pressures or antigen escape. BCMA-CS1 cCAR bears two distinct functional CAR molecules expressed on a T-cell, directed against the surface proteins BCMA and CS1.

Enrollment

12 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Diagnosis based on the World Health Organization (WHO) 2008
  2. Patients have exhausted standard therapeutic options
  3. Systematic usage of immunosuppressive drug or corticosteroid must have been stopped for more than 4 weeks
  4. Female must be not pregnant during the study

Exclusion criteria

  1. Prior solid organ transplantation
  2. Potentially curative therapy including chemotherapy or hematopoietic cell transplant
  3. Prior treatment with BCMAxCD3 or CS1xCD3 bispecific agents

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

12 participants in 1 patient group

BCMA-CD33 cCAR T cells
Experimental group
Description:
BCMA-CS1 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-BCMA and CS1 CARs
Treatment:
Biological: BCMA-CS1 cCAR T cells

Trial contacts and locations

2

Loading...

Central trial contact

Kevin Pinz

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems